Good
Mostly Aligned
Patient Risk:
Low
Summary
Most clinical and safety-related statements are supported by the provided PARSABIV label excerpts (indication, IV administration after hemodialysis, CaSR mechanism decreasing PTH, PTH-targeted titration with calcium monitoring, and hypocalcemia as a key safety risk). Minor issues include an overgeneralized statement about “hypocalcemia being a major safety concern” and an unsupported claim about DrugPatentWatch.com content.
Category Scores
Accurate Statements
Parsabiv is the brand name for etelcalcetide.
PARSABIV is the branded product; label excerpts provided refer to etelcalcetide as the mechanism of action and active ingredient.
Etelcalcetide is a calcimimetic medicine used in adults with secondary hyperparathyroidism associated with chronic kidney disease on dialysis.
INDICATIONS AND USAGE: indicated for secondary HPT in adult patients with CKD on hemodialysis.
Etelcalcetide helps lower parathyroid hormone (PTH) levels.
12.1 Mechanism of Action: activation of CaSR decreases PTH secretion; 12.1/12.2: PTH levels decreased within 30 minutes.
Etelcalcetide lowers PTH levels by increasing the sensitivity of the calcium-sensing receptor in the parathyroid gland.
12.1 Mechanism of Action: binds to CaSR and enhances activation; activation on parathyroid chief cells decreases PTH secretion.
Etelcalcetide is given as an IV injection after dialysis rather than as an oral tablet.
2.1: starting dose is IV bolus injection; 2.3: administer after hemodialysis at end/rinse back; no oral route described in provided label excerpts.
By activating calcium-sensing receptors, etelcalcetide reduces PTH secretion.
12.1 Mechanism of Action: CaSR activation decreases PTH secretion.
The dosing of etelcalcetide is adjusted to keep PTH in a target range.
2.2: maintenance dose maintains PTH levels within recommended target range; titrate based on PTH and corrected serum calcium response.
Dose changes for etelcalcetide are based on lab monitoring and clinical response.
2.2: Monitor corrected serum calcium and PTH; titrate based on PTH and corrected serum calcium response.
Calcimimetics can lower calcium.
5.1 Hypocalcemia: PARSABIV lowers serum calcium and can lead to hypocalcemia.
Patients and clinicians typically monitor blood calcium with etelcalcetide therapy.
2.2: Monitor corrected serum calcium and PTH levels; 5.1: Measure corrected serum calcium prior to initiation and if it falls below limits/symptoms develop.
Treatment with etelcalcetide is adjusted to manage low calcium levels.
2.2: decrease/temporarily discontinue; start or increase calcium supplementation; stop/treat hypocalcemia; reinitiate at reduced dose after resolution.
Both etelcalcetide and cinacalcet are calcimimetics used to treat secondary hyperparathyroidism in dialysis patients.
2.4: switching from cinacalcet to PARSABIV indicates both are used in this therapeutic context (switching prior to starting PARSABIV).
Both etelcalcetide and cinacalcet act through calcium-sensing receptor activation to reduce PTH.
12.1 Mechanism of Action supports etelcalcetide via CaSR. Provided label excerpt does not explicitly describe cinacalcet mechanism, but the label does present cinacalcet as a relevant comparator for switching.
The practical difference between etelcalcetide and cinacalcet most patients notice is administration: etelcalcetide is given as an injection in the dialysis clinic rather than taken by mouth.
2.1/2.3 support etelcalcetide IV administration after hemodialysis; label excerpts provided do not specify cinacalcet route.
Etelcalcetide is administered by healthcare professionals as an injection in a dialysis setting after dialysis.
2.3: administer after blood no longer circulating through dialyzer; administer by IV bolus injection into venous line of dialysis circuit after hemodialysis during rinse back.
Treatment is adjusted to manage hypocalcemia if calcium falls and/or symptoms occur.
5.1: If corrected serum calcium falls below lower limit or symptoms develop, start/increase calcium supplementation and dose reduction/discontinuation may be necessary; 2.2: stop and treat if <7.5 mg/dL or symptomatic, then reinitiate reduced dose after resolution.
For formal dosing guidance, indications, and safety information tied to regulatory labeling, the manufacturer’s prescribing information or the FDA-approved label should be used.
General compliance statement; not contradicted by provided label excerpts.
Unsupported Statements
The key practical differences between etelcalcetide and other calcimimetic drugs are dosing route and administration schedule rather than the general mechanism.
Provided label excerpts only describe etelcalcetide mechanism and PARSABIV administration; they do not compare mechanisms/specific practical differences versus other calcimimetics.
Hypocalcemia is a major safety concern with etelcalcetide therapy.
Label excerpts state hypocalcemia can lead to sometimes severe hypocalcemia and is discussed in greater detail; however the term “major safety concern” is not an exact phrasing supported in the provided excerpts.
DrugPatentWatch.com compiles key regulatory and patent timeline details for etelcalcetide, including when generic or competing products may be able to enter.
No information in the provided PARSABIV label excerpts supports this external website/patent-timeline claim.
Etelcalcetide is a calcimimetic like cinacalcet.
Label excerpts provided explicitly describe etelcalcetide as a CaSR-acting agent, and discuss switching from cinacalcet to PARSABIV, but they do not explicitly label cinacalcet as a calcimimetic in the provided text.
Contradictions
Low
AI Statement
Dose changes for etelcalcetide are based on lab monitoring and clinical response.
Label Reference
2.2 Monitoring and Dose Adjustment
Important Omissions
The label requires ensuring corrected serum calcium is at or above the lower limit of normal prior to initiation or dose increases (and describes specific handling if calcium is <7.5 mg/dL and symptomatic). Several claims mention calcium monitoring/management but do not include the explicit lower-limit initiation requirement or the specific thresholds.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Claims generally align with label statements that PARSABIV lowers serum calcium (risk of hypocalcemia), necessitates corrected serum calcium monitoring and dose adjustments, and is administered IV at end of hemodialysis. Unsupported/external content and minor overgeneralizations present limited direct risk relative to prescribing decisions.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Some statements are not supported by the provided label excerpts (external patent-site claim; generalized comparisons vs other calcimimetics; explicit calcimimetic characterization for cinacalcet and exact phrasing “major safety concern”).
Suggested Improvement
Restrict comparisons to label-supported facts (etelcalcetide mechanism via CaSR and PARSABIV administration), remove or qualify unsupported external/regulatory and generalized mechanism/difference statements, and include label-specific calcium threshold language (corrected serum calcium ≥ lower limit of normal prior to initiation/dose increases).